NEWS | BEAM Alliance

NEWS

Polyphor to present data on murepavadin and its lead preclinical compound of its novel class of Gram-negative antibiotics at the 29th European Congress of Clinical Microbiology and Infectious Diseases

Allschwil, Switzerland, April 4, 2019

Polyphor AG (SIX: POLN) today announced that 5 abstracts featuring data on its Outer Membrane Targeting Antibiotics (OMPTA), including both its lead product candidate murepavadin (POL7080) and its new medium-spectrum anti Gram-negative lead preclinical compound (POL7306), will be presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) taking place in Amsterdam, Netherlands, from April 13 to16, 2019.

Full PR available here